Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Products

Generics Explore this Topic

Set Alert for Generics

Sandoz Canada Expands Its Portfolio With Generic Vyvanse Launch

Sandoz Canada brings a lisdexamfetamine generic to the market, while its US filing still has tentative approval. Meanwhile, off-patent group CGPA launches a social media campaign to tackle misinformation surrounding generics.

Generic Drugs Launches

Opioid Overdose Reversal Drug Manufacturers Commit To Increased Naloxone Capacities

Hikma, Teva, and other drug manufacturers have committed to increased supply of naloxone and nalmefene as part of a meeting with the White House Office of National Drug Control.

United States Generic Drugs

Amneal Launches Six Injectables With Some To Aid US Drug Shortage

Amneal aims to address the ongoing drug shortage crisis in the US with injectable additions to its portfolio. Meanwhile, the FDA states that it has “made a significant impact” to mitigate shortages, preventing 236 shortages in 2023.

Generic Drugs Market Access

UK Pregabalin Prices Skyrocket In May

Pregabalin topped our table of Biggest Risers in May, in another month of multiple treble-digit-percentage average price increases for the UK generics market.

Generic Drugs Pricing Strategies
See All

Biosimilars Explore this Topic

Set Alert for Biosimilars

Pfizer Calls For Sustainable Approach To Ensure Viability Of Biosimilars Market

Global biosimilars player Pfizer is calling for a more sustainable approach to the market to ensure its long-term viability. In the second part of an exclusive interview, Barry Chester, the firm’s global commercial lead for supportive care oncology, tells Generics Bulletin where the company sees room for improvement.

Biosimilars Strategy

Dr. Reddy’s Aurigene Unit Opens New Indian Biologics Facility

The Dr. Reddy subsidiary CRDMO Aurigene has opened a new biologics facility in India, with plans to finish the plant’s manufacturing capabilities later this year.

India BioPharmaceutical

Alvotech And Stada Are Back With A Denosumab Biosimilar Deal

With an ustekinumab biosimilar launch in Europe just around the corner, Alvotech and Stada have reconsidered the previously dropped denosumab partnership, while commercial rights to the aflibercept biosimilar go back to Alvotech.

Deals Strategy

‘We’ve Got The Broadest Pure-Play Oncology Portfolio In The industry’ – Pfizer Talks Biosimilars

Pfizer is one of the leading players in the global biosimilars market. Barry Chester, the firm’s global commercial lead for supportive care oncology, talks to Generics Bulletin about how the business fits into the firm’s wider interests, in the first part of an exclusive interview.

Biosimilars Strategy
See All

Value-Added Medicines Explore this Topic

Set Alert for Value-Added Medicines

Outlook Sets Out Plans For Ophthalmic Bevacizumab In Europe

Outlook Therapeutics has revealed more details of its European launch strategy for its Lytenava ophthalmic bevacizumab following the product’s formal European Commission approval.

Approvals Launches

What’s Next? Five Things To Look Out For In June

Generics Bulletin previews the most noteworthy and anticipated events for June 2024.

Biosimilars Generic Drugs

Irish Body Calls For Urgent Action To Tackle Drug Shortages

Medicines for Ireland has called for action that would alleviate drug shortages affecting every fifth patient in the country after recently urging strategic reform in the EU.

Biosimilars Generic Drugs

Viatris Reveals Next Steps For Once-Monthly US Copaxone Rival After Rejection

Viatris has revealed the early stages of a battle plan after it was knocked back on US FDA approval for its proposed once-monthly glatiramer acetate ‘GA Depot’ product, a follow-on to Teva’s Copaxone treatment for relapsing forms of multiple sclerosis.

Strategy Sales & Earnings
See All